Fujifilm to develop anti-cancer agents with US MD Anderson Cancer Center

26 November 2013

Japanese digital camera and medical equipment conglomerate Fujifilm revealed that it is to conduct clinical development of three anticancer agents with The University of Texas MD Anderson Cancer Center, one of the world's most distinguished facilities for cancer research and treatment.

This is a move to develop anti-cancer drugs in the USA. To begin with, a Phase I clinical trial for FF-10501 is set to start next spring, and the testing for other agents will follow, the company noted. Financial terms of the collaboration have not been released.

Bucking a downward trend when Japan’s Nikkei dropped 0.8% to 15,495.25 yen in morning trading, Fujifilm rose 4.1% to 2,799 yen, the highest since March 2011, after the firm revealed its cancer research plan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK